255 related articles for article (PubMed ID: 11518711)
1. Mutations in the INK4a/ARF melanoma susceptibility locus functionally impair p14ARF.
Rizos H; Darmanian AP; Holland EA; Mann GJ; Kefford RF
J Biol Chem; 2001 Nov; 276(44):41424-34. PubMed ID: 11518711
[TBL] [Abstract][Full Text] [Related]
2. Genetic Alterations in the INK4a/ARF Locus: Effects on Melanoma Development and Progression.
Ming Z; Lim SY; Rizos H
Biomolecules; 2020 Oct; 10(10):. PubMed ID: 33076392
[TBL] [Abstract][Full Text] [Related]
3. INK4a-ARF alterations and p53 mutations in primary and consecutive squamous cell carcinoma of the head and neck.
Weber A; Bellmann U; Bootz F; Wittekind C; Tannapfel A
Virchows Arch; 2002 Aug; 441(2):133-42. PubMed ID: 12189502
[TBL] [Abstract][Full Text] [Related]
4. Contribution of germline mutations in BRCA2, P16(INK4A), P14(ARF) and P15 to uveal melanoma.
Hearle N; Damato BE; Humphreys J; Wixey J; Green H; Stone J; Easton DF; Houlston RS
Invest Ophthalmol Vis Sci; 2003 Feb; 44(2):458-62. PubMed ID: 12556369
[TBL] [Abstract][Full Text] [Related]
5. Genetic alterations of INK4alpha/ARF locus and p53 in human hepatocellular carcinoma.
Peng CY; Chen TC; Hung SP; Chen MF; Yeh CT; Tsai SL; Chu CM; Liaw YF
Anticancer Res; 2002; 22(2B):1265-71. PubMed ID: 12168936
[TBL] [Abstract][Full Text] [Related]
6. Profiles of the 2 INK4a gene products, p16 and p14ARF, in human reference urothelium and bladder carcinomas, according to pRb and p53 protein status.
Le Frère-Belda MA; Gil Diez de Medina S; Daher A; Martin N; Albaud B; Heudes D; Abbou CC; Thiery JP; Zafrani ES; Radvanyi F; Chopin D
Hum Pathol; 2004 Jul; 35(7):817-24. PubMed ID: 15257544
[TBL] [Abstract][Full Text] [Related]
7. Mutational analysis of selected genes in the TGFbeta, Wnt, pRb, and p53 pathways in primary uveal melanoma.
Edmunds SC; Kelsell DP; Hungerford JL; Cree IA
Invest Ophthalmol Vis Sci; 2002 Sep; 43(9):2845-51. PubMed ID: 12202501
[TBL] [Abstract][Full Text] [Related]
8. INK4a-ARF alterations and p53 mutations in hepatocellular carcinomas.
Tannapfel A; Busse C; Weinans L; Benicke M; Katalinic A; Geissler F; Hauss J; Wittekind C
Oncogene; 2001 Oct; 20(48):7104-9. PubMed ID: 11704835
[TBL] [Abstract][Full Text] [Related]
9. Alterations in the INK4a/ARF locus and their effects on the growth of human osteosarcoma cell lines.
Park YB; Park MJ; Kimura K; Shimizu K; Lee SH; Yokota J
Cancer Genet Cytogenet; 2002 Mar; 133(2):105-11. PubMed ID: 11943335
[TBL] [Abstract][Full Text] [Related]
10. Abnormalities of the ARF-p53 pathway in primary angiosarcomas of the liver.
Weihrauch M; Markwarth A; Lehnert G; Wittekind C; Wrbitzky R; Tannapfel A
Hum Pathol; 2002 Sep; 33(9):884-92. PubMed ID: 12378512
[TBL] [Abstract][Full Text] [Related]
11. Alterations of the INK4a-ARF gene locus in pleomorphic adenoma of the parotid gland.
Weber A; Langhanki L; Schütz A; Wittekind C; Bootz F; Tannapfel A
J Pathol; 2002 Nov; 198(3):326-34. PubMed ID: 12375265
[TBL] [Abstract][Full Text] [Related]
12. The INK4a/ARF locus and melanoma.
Sharpless E; Chin L
Oncogene; 2003 May; 22(20):3092-8. PubMed ID: 12789286
[TBL] [Abstract][Full Text] [Related]
13. Genomic instability, mutations and expression analysis of the tumour suppressor genes p14(ARF), p15(INK4b), p16(INK4a) and p53 in actinic keratosis.
Kanellou P; Zaravinos A; Zioga M; Stratigos A; Baritaki S; Soufla G; Zoras O; Spandidos DA
Cancer Lett; 2008 Jun; 264(1):145-61. PubMed ID: 18331779
[TBL] [Abstract][Full Text] [Related]
14. A melanoma-associated germline mutation in exon 1beta inactivates p14ARF.
Rizos H; Puig S; Badenas C; Malvehy J; Darmanian AP; Jiménez L; Milà M; Kefford RF
Oncogene; 2001 Sep; 20(39):5543-7. PubMed ID: 11571653
[TBL] [Abstract][Full Text] [Related]
15. Aberrations of the p14(ARF) and p16(INK4a) genes in renal cell carcinomas.
Kawada Y; Nakamura M; Ishida E; Shimada K; Oosterwijk E; Uemura H; Hirao Y; Chul KS; Konishi N
Jpn J Cancer Res; 2001 Dec; 92(12):1293-9. PubMed ID: 11749694
[TBL] [Abstract][Full Text] [Related]
16. Genetic status of cell cycle regulators in squamous cell carcinoma of the oesophagus: the CDKN2A (p16(INK4a) and p14(ARF) ) and p53 genes are major targets for inactivation.
Smeds J; Berggren P; Ma X; Xu Z; Hemminki K; Kumar R
Carcinogenesis; 2002 Apr; 23(4):645-55. PubMed ID: 11960918
[TBL] [Abstract][Full Text] [Related]
17. CDKN2A point mutations D153spl(c.457G>T) and IVS2+1G>T result in aberrant splice products affecting both p16INK4a and p14ARF.
Rutter JL; Goldstein AM; Dávila MR; Tucker MA; Struewing JP
Oncogene; 2003 Jul; 22(28):4444-8. PubMed ID: 12853981
[TBL] [Abstract][Full Text] [Related]
18. INK4a/ARF locus alterations in human non-Hodgkin's lymphomas mainly occur in tumors with wild-type p53 gene.
Pinyol M; Hernández L; Martínez A; Cobo F; Hernández S; Beà S; López-Guillermo A; Nayach I; Palacín A; Nadal A; Fernández PL; Montserrat E; Cardesa A; Campo E
Am J Pathol; 2000 Jun; 156(6):1987-96. PubMed ID: 10854221
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of p14ARF, p15INK4b, and p16INK4a inactivation in malignant peripheral nerve sheath tumors.
Endo M; Kobayashi C; Setsu N; Takahashi Y; Kohashi K; Yamamoto H; Tamiya S; Matsuda S; Iwamoto Y; Tsuneyoshi M; Oda Y
Clin Cancer Res; 2011 Jun; 17(11):3771-82. PubMed ID: 21262917
[TBL] [Abstract][Full Text] [Related]
20. p16INK4a and p14ARF methylation as a potential biomarker for human bladder cancer.
Kawamoto K; Enokida H; Gotanda T; Kubo H; Nishiyama K; Kawahara M; Nakagawa M
Biochem Biophys Res Commun; 2006 Jan; 339(3):790-6. PubMed ID: 16316628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
